Trials
3 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET, Metastatic Breast Cancer and 10 more
- Main trialPhase 3
- “This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity…”In the company’s words, NCT05477576 on ClinicalTrials.gov
Other drugs for GEP-NET
- CAM2029Camurus AB · Phase 3
- 177Lu-edotreotide PRRTITM Solucin GmbH · Phase 3
- VMT-α-NETPerspective Therapeutics · Phase 1/2
- CVM-1118TaiRx, Inc. · Phase 2
- Lu-DOTA-TATENovartis Pharmaceuticals · Phase 2
- RYZ401RayzeBio, Inc. · Phase 1
Coming up3
- DecPhase 3 trial completes · ClinicalTrials.gov
- Jul 2027Phase 1 trial completes · ClinicalTrials.gov
- Oct 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2026 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | |
| Phase 1/2Recruiting | Oct 2028 | Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. | |
| Phase 1Active, not recruiting | Jul 2027 | Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026